Interestingly, Fujiwara H et al. reported that AML patients with IDH mutations had a 14-fold higher response rate to BET inhibitors than common patients.491 The combination strategy of IDH inhibitors with the DNMT inhibitor azacitidine in AML treatment has also been evaluated in several clinical trials, and the preliminary results are encouraging.492,493. This evidence concerns the gene IDH2 and acute myeloid leukemia.